Immutep says eftilagimod alfa plus standard care boosts overall survival in late-stage cancer study analysis

• Immutep disclosed a pooled evaluation of five eftilagimod alfa combination trials in late-stage cancers, linking immune activation to better survival outcomes.
• Results have not yet been presented; the data are scheduled for a poster at the ASCO Annual Meeting on May 30, 2026.
• Patients showing a treatment-related immune response tended to live longer than non-responders, a pattern not seen with standard therapy alone.
• Findings were consistent across multiple tumor types and across combinations with chemotherapy or PD-1-based immunotherapy.
• The analysis excluded the discontinued TACTI-004 Phase III lung cancer trial, limiting read-through to earlier-stage studies.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Immutep Ltd. published the original content used to generate this news brief on May 28, 2026, and is solely responsible for the information contained therein.